Santen China signs AbbVie deal for exclusive distribution of five glaucoma eyedrops
PUBT · 2d ago
Share
Listen to the news
- Santen China entered distribution and promotion agreement with AbbVie for five marketed glaucoma eyedrops in Chinese mainland.
- Deal grants Santen China exclusive distribution rights for AbbVie products including Alphagan, Lumigan, Combigan.
- Agreement expands Santen glaucoma portfolio in China, adding brimonidine-based products alongside existing prostaglandin-related therapies.
- Partnership targets growth in China glaucoma market, where patient population exceeded 21.8 million in 2020.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Santen Pharmaceutical Co. Ltd. published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending